These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 18720513)

  • 1. HIV entry inhibitors and their potential in HIV therapy.
    Qian K; Morris-Natschke SL; Lee KH
    Med Res Rev; 2009 Mar; 29(2):369-93. PubMed ID: 18720513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors.
    Chen W; Zhan P; De Clercq E; Liu X
    Curr Pharm Des; 2012; 18(1):100-12. PubMed ID: 22236118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 entry inhibitors: an overview.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 entry inhibitors: classes, applications and factors affecting potency.
    Sterjovski J; Churchill MJ; Wesselingh SL; Gorry PR
    Curr HIV Res; 2006 Oct; 4(4):387-400. PubMed ID: 17073614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targets for antiretroviral therapy: clinical progress to date.
    Dau B; Holodniy M
    Drugs; 2009; 69(1):31-50. PubMed ID: 19192935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.
    Pugach P; Ketas TJ; Michael E; Moore JP
    Virology; 2008 Aug; 377(2):401-7. PubMed ID: 18519143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIV entry inhibitors revisited.
    Leonard JT; Roy K
    Curr Med Chem; 2006; 13(8):911-34. PubMed ID: 16611075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Conclusions and perspectives. Maraviroc].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drug targets for antiretroviral therapy.
    Reeves JD; Piefer AJ
    Drugs; 2005; 65(13):1747-66. PubMed ID: 16114975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV co-receptor CCR5: structure and interactions with inhibitors.
    Wang T; Duan Y
    Infect Disord Drug Targets; 2009 Jun; 9(3):279-88. PubMed ID: 19519482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.